Clinical Trial

Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage kidney disease, affecting 25-40% of type 1 diabetes (T1D) patients and 5-40% of type 2 diabetes (T2D) patients. Despite standard treatments like ACE inhibitors and ARBs, many patients continue to develop DKD, indicating a need for better kidney protection. This study aims to evaluate the efficacy and safety of dapagliflozin combined with insulin in early DKD patients with T1DM, using ACEi/ARB as standard treatment, to provide new insights into kidney protection and support precision medicine goals.
Trial Details
NCT Number NCT06532682
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Diabetic Kidney Disease, Type 1 Diabetes
Enrollment 54 participants
Start Date 2024-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-01